Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

Vaccine

Volumn 32, Issue 48, 2014, Pages 6377-6389

  Scheiermann, Julia ^a   Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Cancer; CpG olignucleotide; Infection; Toll like receptor

Indexed keywords

ANTHRAX VACCINE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; TOLL LIKE RECEPTOR 9; VIRUS VACCINE; CPG-OLIGONUCLEOTIDE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN; VACCINE;

ADJUVANT THERAPY; ANTHRAX; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CANCER PREVENTION; CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CPG ISLAND; DRUG FEVER; DRUG SAFETY; DRUG TARGETING; FATIGUE; FLU LIKE SYNDROME; FOCAL EPILEPSY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFLUENZA; INJECTION SITE REACTION; INNATE IMMUNITY; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGOR; SIDE EFFECT; SIGNAL TRANSDUCTION; TONIC CLONIC SEIZURE; VACCINATION; B LYMPHOCYTE; CHEMISTRY; DENDRITIC CELL; IMMUNOLOGY; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; B-LYMPHOCYTES; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TH1 CELLS; TOLL-LIKE RECEPTOR 9; VACCINES;

EID: 84908592762     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.065     Document Type: Review

References (143)

1. Klein U., la-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008, 8:22-33.
2. Weill J.C., Weller S., Reynaud C.A. Human marginal zone B cells. Annu Rev Immunol 2009, 27:267-285.
3. Schmidlin H., Diehl S.A., Blom B. New insights into the regulation of human B-cell differentiation. Trends Immunol 2009, 30:277-285.
4. Ahlers J.D., Belyakov I.M. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010, 115:1678-1689.
5. Cockburn I.A., Chen Y.C., Overstreet M.G., et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 2010, 6:e1000877.
6. Guimond M., Veenstra R.G., Grindler D.J., et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 2009, 10:149-157.
7. Vezys V., Yates A., Casey K.A., et al. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 2009, 457:196-199.
8. Roach J.C., Glusman G., Rowen L., et al. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005, 102:9577-9582.
9. Vacchelli E., Eggermont A., Sautes-Fridman C., et al. Trial Watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013, 2:e25238.
10. Eaton-Bassiri A., Dillon S.B., Cunningham M., et al. Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells. Infect Immun 2004, 72:7202-7211.
11. Akira S., Takeda K. Functions of toll-like receptors: lessons from KO mice. C R Biol 2004, 327:581-589.
12. Tuomela J., Sandholm J., Karihtala P., et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat 2012, 135:481-493.
13. Hagstrom J., Heikkila A., Siironen P., et al. TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma. J Clin Pathol 2012, 65:333-338.
14. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9:57-63.
15. Latz E., Schoenemeyer A., Visintin A., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004, 5:190-198.
16. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
17. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. NAT 2000, 408:740-745.
18. Hornung V., Rothenfusser S., Britsch S., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
19. Suzuki Y., Wakita D., Chamoto K., et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004, 64:8754-8760.
20. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001, 194:863-869.
21. Bernasconi N.L., Onai N., Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101:4500-4504.
22. Bourke E., Bosisio D., Golay J., Polentarutti N., Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003, 102:956-963.
23. Browne E.P. Regulation of B-cell responses by Toll-like receptors. Immunology 2012, 136:370-379.
24. Dement-Brown J., Newton C.S., Ise T., Damdinsuren B., Nagata S., Tolnay M. Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes. J Leukoc Biol 2012, 91:59-67.
25. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30:16-34.
26. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
27. Kaisho T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine 2012, 30:7652-7657.
28. Ewald S.E., Lee B.L., Lau L., et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-662.
29. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008, 9:1407-1414.
30. Ewald S.E., Engel A., Lee J., Wang M., Bogyo M., Barton G.M. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 2011, 208:643-651.
31. Sepulveda F.E., Maschalidi S., Colisson R., et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009, 31:737-748.
32. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
33. Lahoud M.H., Ahmet F., Zhang J.G., et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci USA 2012, 109:16270-16275.
34. Mutwiri G.K., Nichani A.K., Babiuk S., Babiuk L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 2004, 97:1-17.
35. Verthelyi D., Ishii K.J., Gursel M., Takeshita F., Klinman D.M. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001, 166:2372-2377.
36. Hartmann G., Battiany J., Poeck H., et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003, 33:1633-1641.
37. Krug A., Towarowski A., Britsch S., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31:3026-3037.
38. Guiducci C., Ott G., Chan J.H., et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006, 203:1999-2008.
39. Honda K., Ohba Y., Yanai H., et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434:1035-1040.
40. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004, 172:1777-1785.
41. Goldinger S.M., Dummer R., Baumgaertner P., et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol 2012, 42:3049-3061.
42. Speiser D.E., Schwarz K., Baumgaertner P., et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010, 33:848-858.
43. Marshall J.D., Fearon K., Abbate C., et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003, 73:781-792.
44. Vollmer J., Weeratna R., Payette P., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34:251-262.
45. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009, 61:195-204.
46. Samulowitz U., Weber M., Weeratna R., et al. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 2010, 20:93-101.
47. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997, 94:10833-10837.
48. Klinman D.M., Currie D., Lee G., Grippe V., Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect 2007, 9:1478-1483.
49. Kamal S., Rashid A.M., Bakar M., Ahad M. Anthrax: an update. Asian Pac J Trop Biomed 2011, 1:496-501.
50. Geier D.A., Geier M.R. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin Exp Rheumatol 2002, 20:217-220.
51. Ready T. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat Med 2004, 10:112.
52. Gu M., Hine P.M., James J.W., Giri L., Nabors G.S. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 2007, 25:526-534.
53. Rynkiewicz D., Rathkopf M., Sim I., et al. Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 2011, 29:6313-6320.
54. Hopkins R.J., Daczkowski N.F., Kaptur P.E., et al. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine 2013, 31:3051-3058.
55. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
56. Bai J.Y., Yang Y.T., Zhu R., et al. CpG oligodeoxynucleotides discriminately enhance binding capacity of human naive B cells to Hepatitis B virus epitopes. Can J Microbiol 2012, 58:752-759.
57. Wang S., Han Q., Zhang G., et al. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. Int Immunopharmacol 2011, 11:406-411.
58. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998, 161:4463-4466.
59. Davis H.L., Suparto I.I., Weeratna R.R., et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000, 18:1920-1924.
60. Freed D.C., Towne V.M., Casimiro D.R., Zhao Q., Fu T.M. Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations. Vaccine 2011, 29:9385-9390.
61. Cooper C.L., Davis H.L., Morris M.L., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24:693-701.
62. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.
63. Halperin S.A., Dobson S., McNeil S., et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006, 24:20-26.
64. Halperin S.A., Ward B., Cooper C., et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012, 30:2556-2563.
65. Sablan B.P., Kim D.J., Barzaga N.G., et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30:2689-2696.
66. Gupta S., Gunter J.T., Novak R.J., Regens J.L. Patterns of Plasmodium vivax and Plasmodium falciparum malaria underscore importance of data collection from private health care facilities in India. Malar J 2009, 8:227.
67. Ellis R.D., Sagara I., Doumbo O., Wu Y. Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 2010, 6:627-634.
68. Langhorne J., Ndungu F.M., Sponaas A.M., Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008, 9:725-732.
69. Lanzavecchia A., Bernasconi N., Traggiai E., Ruprecht C.R., Corti D., Sallusto F. Understanding and making use of human memory B cells. Immunol Rev 2006, 211:303-309.
70. Sanz I., Wei C., Lee F.E., Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008, 20:67-82.
71. Kennedy M.C., Wang J., Zhang Y., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002, 70:6948-6960.
72. Dutta S., Sullivan J.S., Grady K.K., et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009, 4:e8138.
73. Dicko A., Diemert D.J., Sagara I., et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One 2007, 2:e1045.
74. Sagara I., Ellis R.D., Dicko A., et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 2009, 27:7292-7298.
75. Crompton P.D., Mircetic M., Weiss G., et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 2009, 182:3318-3326.
76. Mullen G.E., Ellis R.D., Miura K., et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 2008, 3:e2940.
77. Ellis R.D., Martin L.B., Shaffer D., et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 2010, 5:e8787.
78. Duncan C.J., Sheehy S.H., Ewer K.J., et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 2011, 6:e22271.
79. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998, 16:1216-1224.
80. Rhee J.W., Kim D., Park B.K., et al. Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice. PLoS One 2012, 7:e48750.
81. Fang Y., Rowe T., Leon A.J., et al. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J Virol 2010, 84:8369-8388.
82. Cooper C.L., Davis H.L., Morris M.L., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22:3136-3143.
83. Lopez-Palomo C., Martin-Zamorano M., Benitez E., et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004, 72:517-524.
84. Hersperger A.R., Pereyra F., Nason M., et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010, 6:e1000917.
85. Agrawal S., Agrawal A., Doughty B., et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003, 171:4984-4989.
86. Scheller C., Ullrich A., McPherson K., et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004, 279:21897-21902.
87. Equils O., Schito M.L., Karahashi H., et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003, 170:5159-5164.
88. Sulkowski M.S., Chaisson R.E., Karp C.L., Moore R.D., Margolick J.B., Quinn T.C. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998, 178:1642-1648.
89. Rotchford K., Strum A.W., Wilkinson D. Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis 2000, 27:243-248.
90. Cooper C.L., Davis H.L., Angel J.B., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473-1479.
91. Angel J.B., Cooper C.L., Clinch J., et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Based Ther Vaccines 2008, 6:4.
92. Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46:1310-1314.
93. Sogaard O.S., Lohse N., Harboe Z.B., et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010, 51:42-50.
94. Offersen R., Melchjorsen J., Paludan S.R., Ostergaard L., Tolstrup M., Sogaard O.S. TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Hum Vaccin Immunother 2012, 8:1042-1047.
95. Winckelmann A.A., Munk-Petersen L.V., Rasmussen T.A., et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 2013, 8:e62074.
96. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004, 6:88-95.
97. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999, 59:5429-5432.
98. Carpentier A.F., Xie J., Mokhtari K., Delattre J.Y. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000, 6:2469-2473.
99. Shirota Y., Shirota H., Klinman D.M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012, 188:1592-1599.
100. Carpentier A., Laigle-Donadey F., Zohar S., et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 2006, 8:60-66.
101. Carpentier A., Metellus P., Ursu R., et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010, 12:401-408.
102. Lienard D., Rimoldi D., Marchand M., et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004, 4:4.
103. Cormier J.N., Salgaller M.L., Prevette T., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997, 3:37-44.
104. Ramos T.C., Vinageras E.N., Ferrer M.C., et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 2006, 5:145-149.
105. Gonzalez G., Crombet T., Catala M., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998, 9:431-435.
106. Perales M.A., Yuan J., Powel S., et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008, 16:2022-2029.
107. Krug L.M., Dao T., Brown A.B., et al. WT1 peptide vaccinations induce CD4 and CD8T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1467-1479.
108. Jager E., Nagata Y., Gnjatic S., et al. Monitoring CD8T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000, 97:4760-4765.
109. Baumgaertner P., Rufer N., Devevre E., et al. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res 2006, 66:1912-1916.
110. Barve M., Bender J., Senzer N., et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008, 26:4418-4425.
111. Vansteenkiste J., Zielinski M., Linder A., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31:2396-2403.
112. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10:499-511.
113. Shirota H., Klinman D.M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 2014, 13:299-312.
114. Ursu R., Carpentier A.F. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol 2012, 746:95-108.
115. Baumgaertner P., Jandus C., Rivals J.P., et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer 2012, 130:2607-2617.
116. Tarhini A.A., Leng S., Moschos S.J., et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 2012, 35:359-366.
117. Del V.M., Di G.L., Ascierto P.A., et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014, 50:121-127.
118. Ohno S., Okuyama R., Aruga A., Sugiyama H., Yamamoto M. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res 2012, 32:2263-2269.
119. Heikenwalder M., Polymenidou M., Junt T., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10:187-192.
120. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 1999, 162:2368-2374.
121. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27:460-471.
122. Leonard J.P., Link B.K., Emmanouilides C., et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007, 13:6168-6174.
123. Manegold C., Gravenor D., Woytowitz D., et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3979-3986.
124. Witzig T.E., Wiseman G.A., Maurer M.J., et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol 2013, 88:589-593.
125. Krieg A.M., Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007, 220:251-269.
126. Ellis R.D., Mullen G.E., Pierce M., et al. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 2009, 27:4104-4109.
127. Kim Y.H., Girardi M., Duvic M., et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010, 63:975-983.
128. Karbach J., Neumann A., Atmaca A., et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res 2011, 17:861-870.
129. Speiser D.E., Lienard D., Rufer N., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115:739-746.
130. Schlom J. Recombinant cancer vaccines and new vaccine targets. Expert Rev Vaccines 2013, 12:1121-1124.
131. Fujiki F., Oka Y., Kawakatsu M., et al. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 2010, 30:2247-2254.
132. Klebanoff C.A., Gattinoni L., Restifo N.P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006, 211:214-224.
133. Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995, 182:1609-1614.
134. Madan R.A., Bilusic M., Heery C., Schlom J., Gulley J.L. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012, 39:296-304.
135. Miura K., Zhou H., Moretz S.E., et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 2008, 181:8776-8783.
136. Traore B., Kone Y., Doumbo S., et al. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 2009, 27:7299-7303.
137. Ellis R.D., Wu Y., Martin L.B., et al. Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against P. falciparum malaria. PLoS One 2012, 7:e46094.
138. La R.C., Longmate J., Lacey S.F., et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012, 205:1294-1304.
139. Halperin S.A., McNeil S., Langley J.M., et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012, 30:5445-5448.
140. Fourcade J., Kudela P., ndrade Filho P.A., et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008, 31:781-791.
141. Valmori D., Souleimanian N.E., Tosello V., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8T cells through cross-priming. Proc Natl Acad Sci USA 2007, 104:8947-8952.
142. Karbach J., Gnjatic S., Bender A., et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010, 126:909-918.
143. Iwahashi M., Katsuda M., Nakamori M., et al. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 2010, 101:2510-2517.